Gamma-aminobutyric acid type A receptor alpha-5 beta-3 gamma-2 subtype (GABA_A receptor α5β3γ2) (GABA_A receptor α5β3γ2)

The Gamma-aminobutyric acid type A (GABA_A) receptor alpha-5 beta-3 gamma-2 subtype is a specific heteropentameric ligand-gated ion channel that mediates inhibitory neurotransmission in the central nervous system [1, 2]. Predominantly expressed in the hippocampus and cerebral cortex, this subtype is primarily located extrasynaptically where it mediates tonic inhibition, a persistent chloride current that regulates neuronal excitability and synaptic plasticity [3, 4]. This unique physiological role makes the alpha-5-containing receptor a critical modulator of cognitive processes, including learning, memory consolidation, and spatial navigation [3]. Dysregulation or altered expression of this receptor subtype has been implicated in the pathophysiology of various conditions, such as Alzheimer's disease, schizophrenia, Down syndrome, and autism spectrum disorders [2, 3, 6]. From a therapeutic perspective, the alpha-5 beta-3 gamma-2 subtype is a target for both positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) [1, 3]. NAMs like Basmisanil and L-655,708 are designed to enhance cognition by reducing tonic inhibition, showing promise in treating cognitive deficits associated with Down syndrome and aging [3]. Conversely, PAMs such as GL-II-73 are being developed to alleviate cognitive impairment in depression and age-related cognitive decline [3]. While selective targeting of this subtype aims to minimize the sedation and ataxia associated with other GABA_A receptors, potential safety concerns include a lowered seizure threshold for NAMs and mild sedative effects for PAMs [1, 6]. The receptor's benzodiazepine binding site, located at the alpha-5/gamma-2 interface, is the primary site of action for these modulatory drugs [1, 3]. Overall, the α5β3γ2 subtype represents a high-value target for precision medicine in neuropsychiatry due to its restricted expression and specialized cognitive functions [3, 4].

Other names

α5β3γ2 GABAA receptorAlpha-5-containing GABAA receptorGABRA5/GABRB3/GABRG2 complexGABRA5 receptor

Positive allosteric modulation (PAM), negative allosteric modulation (NAM), and competitive antagonism at the benzodiazepine binding site [1, 3].